Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search


Specific immune cells predict bowel cancer outcomes

Monday 6 March 2017

Specific immune cells predict bowel cancer outcomes

A pilot study by University of Otago researchers suggests that people with colorectal cancer that have a certain type of immune cell in their tumour may have increased survival rates.

The Department of Microbiology and Immunology researchers found that people with more "effector T regulatory (Treg)" immune cells present in their colorectal tumours were more likely to be disease-free for longer than those who had fewer of these cells.

The study involved 32 individuals with early stage (II) colorectal cancer. These patients were followed up for more than 5 years and 13 individuals had recurrence of their cancer over this time and 19 individuals did not. The findings appear in the international journal Cancer Immunology, Immunotherapy.

Using a new tool to measure basic immune cell infiltrates in tumours, the Immunoscore, and measuring more complex immune cells, the research looked at which type of immune responses were associated with patient survival.

The researchers found that although the Immunoscore was better than the current staging at estimating patient survival, adding “effector Treg” immune cells made it even better.

Study co-author and PhD student Kirsten Ward-Hartstonge says the study findings mean that it could be possible to measure immune responses in colorectal cancer patients to estimate which patients are likely to get their cancer back and should therefore be given additional treatment.

“This information could be used to tailor existing therapies to be targeted to people who really need them, rather than taking a more blanket approach,” Miss Ward-Hartstonge says.

Around a quarter of patients who are currently considered “low risk” by current staging methods will eventually develop the disease again, she says.

These patients usually do not receive chemotherapy or radiotherapy because the risks and costs were thought to outweigh the benefits.

“By measuring an individual patient’s Immunoscore and ‘effector Treg’ immune cells, it may be possible to more accurately identify patients at high risk of getting their disease back and treating them more effectively,” she says.

Other research has shown that New Zealand and Australia have the highest rates of colorectal cancer incidence and death in the world.

The research is collaboration between the Departments of Microbiology and Immunology, and Surgical Sciences at the University of Otago. It was funded by the Genesis Oncology Trust and Lottery Health Research.


© Scoop Media

Business Headlines | Sci-Tech Headlines


NZ's Space Programme: Rocket Lab Makes It To Space (But Not Orbit)

Electron lifted-off at 16:20 NZST from Rocket Lab Launch Complex 1 on the Mahia Peninsula in New Zealand. It was the first orbital-class rocket launched from from a private launch site in the world. More>>



Budget: Irrigate (Good Times, Come On!)

Additional grant funding of $26.7 million over the next three years plus a capital boost of $63 million towards irrigation investments in Budget 2017 will deliver economic and environmental benefits through better use of water... More>>


Silver Fern Farms: Proposal To Close Fairton Sheepmeat Plant

Silver Fern Farms has advised its people of the proposal to permanently close the site, and has discussed potential transfer options to its other sites in the region as part of the consultation process...


MPI: Myrtle Rust Appears In Taranaki

The nursery in Waitara (just north of New Plymouth) reported suspected myrtle rust symptoms on young plants to the Ministry’s 0800 number yesterday (Tuesday). More>>